Overture Life and Spectrun Bio Partner to Bring Automated IVF to Brazil, Advancing Mission to Scale Consistent Embryology Across Latin America

PALO ALTO, Calif. & SÃO PAULO--(BUSINESS WIRE)--Overture Life, the global leader in automated IVF, and Spectrun Bio, a specialist in life sciences commercialization and clinical support across Brazil, today announced a strategic partnership to bring the DaVitri automated IVF laboratory platform to Latin America's largest and most active fertility market. By combining Overture's proven automation technology with Spectrun Bio's deep market knowledge, clinical relationships, and local support infrastructure, the partnership is designed to give Brazilian IVF clinics a credible, fully supported path to implementing robotic embryology and to advance both organizations' shared mission of making consistent, reproducible IVF care more widely available.

DaVitri, cleared by Brazil's National Health Surveillance Agency (ANVISA) as a class I medical device and carrying CE Mark approval, automates vitrification, one of the most technically demanding steps in the IVF laboratory workflow. The platform uses a regulated, microfluidic system to reduce the operator-dependent variability that has long made procedural consistency in embryology a function of individual technician skill rather than systemic reliability.

Brazil ranks among the top countries globally for annual IVF cycle volume, yet the quality of care a patient receives can still vary significantly based on which embryologist performs a given procedure on a given day. For patients, that inconsistency is not an operational issue it is the difference between a successful outcome and another round of treatment.

“Brazil has the patient volume, the clinical talent, and the networks that make automation not just viable but overdue, said Overture Life CEO Hans Gangeskar. “This partnership succeeds because of what Spectrun Bio brings: local accountability, local training, local support, and a deep understanding of how IVF actually operates in this market.”

For Spectrun Bio, the partnership represents the culmination of a years-long focus on identifying the technologies best positioned to raise the standard of fertility care in Brazil. The organization brings established relationships across leading IVF networks and the operational infrastructure implementation support, clinical training, and ongoing service continuity that determines whether new laboratory technology actually integrates successfully into daily clinic operations.

“The conversation about automating IVF has been happening in Brazil for years. Overture Life’s DaVitri is the platform we have been waiting to bring to market: cleared, proven across multiple Latin American countries, and designed in a way that clinics here can realistically deploy and sustain. This partnership is how that conversation becomes action,” said Spectrun CEO Paulo Neto.

The partnership is structured to ensure that clinics receive access to the DaVitri platform and the training, implementation support, and service continuity that make adoption reliable. Clinics in other markets that have deployed DaVitri have reported improvements in procedural consistency and embryologist workload, enabling their teams to concentrate on the higher-complexity judgment work that automation cannot replace.

“Fertility networks in Brazil are under real pressure with growing patient demand, limited specialist supply, and expectations from investors and patients alike for measurable, reproducible outcomes, said Overture Life Chief Commercial Officer Matt Combs. The clinics that move first on automation will set the benchmark that the rest of the market is measured against. Spectrun Bio gives DaVitri the commercial foundation to make that happen at scale, and we expect significant interest across the region as word spreads that this technology is live, supported, and operating in Brazil.”

Clinics in Brazil and across Latin America interested in DaVitri can contact info@overture.life and visit https://www.overture.life/davitri.

About Overture Life

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly egg freezing and embryo handling in ways that increase throughput and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture combines robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in egg freezing, giving women and families worldwide more control over their fertility timelines. Overture's investors include Overwater Ventures, GV, Khosla Ventures, Octopus Ventures, and others committed to advancing the future of fertility.

About Spectrun Bio

Spectrun is Brazil’s leading distributor of advanced laboratory solutions, serving Human and Animal Reproduction as well as Research and Development. With nearly five decades of expertise, it delivers a complete ecosystem of technologies, consumables, technical support, and specialized consulting. Recognized as a trusted partner, Spectrun helps laboratories operate with greater precision, efficiency, and consistency.